An Analysis of Clinical Efficacy Based on the Robotic, Laparoscopic, and Open Approach in Radical Resection of Rectal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03911167

Enrollment

Registered

2019-04-10

Start date

2017-09-01

Completion date

2018-07-01

Last updated

2019-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Brief summary

A retrospective study was done on the medical records for 24 rectal cancer patients underwent robotic proctectomy from September 2017 to July 2018 at the First Afﬁliated Hospital of Xi'an Jiaotong University.In the same department,a total of 25 patients who treated with laparoscopic proctectomy and 24 patients underwent open proctectomy were were selected as controls in a 1:1:1 ratio. Comparing the perioperative conditions and hospitalization related costs of the three groups.

Interventions

PROCEDUREopen, laparoscopic, and robotic

Radical resection of rectal cancer in robotic, laparoscopic, and open approach

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* endoscopic biopsy pathological diagnosis of rectal cancer is clear, preoperative CT, MRI examination did not see the tumor directly invaded the surrounding organs; * blood test, cardiac ultrasound, lung ventilation function and other preoperative examination without absolute surgical contraindications; * without distant metastasis such as liver, lung, bone, and abdominal cavity.

Exclusion criteria

* there is distant organ transfer or extensive abdominal metastasis; * emergency surgery for acute intestinal obstruction, hemorrhage, perforation, intestinal rupture, etc.; * combined with other primary malignant tumors; * other colonectomy and combined with other organ resection; * patients with severe basic diseases unable to tolerate surgery; * pregnant and lactating women; * patients who underwent neoadjuvant radiotherapy and chemotherapy before surgery; * those who underwent palliative surgery.

Design outcomes

Primary

Measure	Time frame
Postoperative complication rate，%	2 weeks

Secondary

Measure	Time frame
operation time,minutes;	2 weeks
intraoperative bleeding,ml;	2 weeks
number of lymph node detection,	2 weeks
Urine tube time,days;	2 weeks
intake time, days;	2 weeks
postoperative hospital stay,days;	2 weeks
hospitalization expenses,yuan	2 weeks
exhaust time,days;	2 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026